Arpita Desai is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 78 publications with 2,549 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
3 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.8%Kinase inhibitor40.6%Inlyta46%Cabometyx38%Fotivda17%Part D<11 patientsCytochrome P450 17A1 Inhibitor15.7%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
20.3%Corticosteroid20.3%Prednisone100%Part D≥11 patientsHormonal (systemic)
11.5%l-Thyroxine11.5%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
Journal for ImmunoTherapy of Cancer
2026 - YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study
Journal of the National Comprehensive Cancer Network
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Talmadge King, MD
University of California, San Francisco
Adil Daud, MD
University of California, San Francisco
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”